If you want blockbuster sales, buy them in
An analysis of recent US drug sales confirms the growing role of licensing and acquisitions, though the biggest sellers conceal some interesting nuance.
Should gene therapy patients be asked to pay?
The price in value-based payment deals should by definition be justified, so why is patient cost-sharing part of the calculation? Spark covers this cost, but there is no…
Lilly hopes volume can make up for late migraine entry
In a constrained pricing environment a volume play could help sales of Lilly's Emgality as it takes on Amgen’s Aimovig and Teva’s Ajovy.
As the US shutdown rolls on, blockbuster launches line up for 2019
A look at the biggest potential drug launches this year reveals a long list of blockbusters from the likes of Alexion and Abbvie. But what impact will the shutdown have?
JP Morgan 2019 – Alnylam turns Onpattro frown upside-down
Alnylam appears to have turned its Onpattro launch around, but is adamant that investors should have been more patient all along.
Ash 2018 – Sobi still has a mountain to climb with Gamifant
Launch could be trickier than approval, not least because of problems diagnosing patients with primary haemophagocytic lymphohistiocytosis.
Patience is a virtue for big pharma buyers
For biotechs nearing regulatory approval the key is to sell before launch. For buyers, playing the waiting game is a better strategy.
The most disputed sales outlooks in biopharma
Celgene’s Revlimid ranks as biopharma’s most contested blockbuster, with a huge spread in future sales forecasts, while drugs from Bristol-Myers Squibb and Sanofi also…
Cost-effectiveness doubts could hit Shire’s Takhzyro launch
A damning report by the US pricing watchdog Icer could bode ill for the uptake of Shire’s big hereditary angioedema hope.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.